New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:54 EDTISISNEJM publishes study on loss-of-function mutations in APOC3
An article in the New England Journal of Medicine concluded, "Rare mutations that disrupt APOC3 function were associated with lower levels of plasma triglycerides and APOC3. Carriers of these mutations were found to have a reduced risk of coronary heart disease." Isis Pharmaceuticals is advancing an APOC3 antisense program into Phase 3, says Piper Jaffray. The firm believes the NEJM article further supports a role for the product beyond the pancreatitis-lowering benefit. Reference Link]:[http://www.nejm.org/doi/full/10.1056/NEJMoa1307095?query=featured_home]
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use